Merck's KEYTRUDA ® (pembrolizumab) Approved in Japan for three additional first-line indications around RCC and chronic or remote metastatic head and neck cancer

Merck’s KEYTRUDA ® (pembrolizumab) Approved in Japan for three additional first-line indications around RCC and chronic or remote metastatic head and neck cancer

KENILWORTH, N.J.-(BUSINESS WIRE)- Merck, branded as MSD outside the United States and Canada, today announced that for the following additional uses in Japan, KEYTRUDA, Merck’s anti-PD-1 medication, received new approvals from the Japan Pharmaceutical and Medical Devices Agency for advanced…